Updates on vaccinating the inflammatory bowel disease patient

Zullow, Samantha; Farraye, Francis A.

doi:10.1080/17474124.2019.1565993

Cited by 18 publications

(17 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Live-attenuated vaccines should be avoided within the 3 months after immunosuppressants have been stopped. According to certain experts 31 , this delay may be reduced in cases of low levels of immunosuppression, One month is sufficient if corticosteroids are used alone.…”

Section: When Should Vaccines Be Administrated?mentioning

confidence: 99%

Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases

Beaugerie

Rahier

Kirchgesner

2020

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

Section: When Should Vaccines Be Administrated?mentioning

confidence: 99%

Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases

Beaugerie

Rahier

Kirchgesner

2020

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

“…Inactivated vaccines, also known as killed vaccines, use dead virus or bacterium to stimulate antibody production by triggering an immune response [20]. Inactivated vaccines are safe regardless of immunosuppression status [21]. However, it is recommended that administration be completed at least 2 weeks before initiating immunosuppressive therapy to maximize the effect of the vaccination [14].…”

Section: Two Main Types Of Vaccinesmentioning

confidence: 99%

“…Inactivated vaccines generally provide weaker immunity than live vaccines, so subsequent booster shots are often required [22]. Live attenuated vaccines, in-cluding measles, mumps, and rubella (MMR), herpes zoster (HZ), and varicella vaccines should not be administered to patients undergoing immunosuppressive treatment due to the risk of developing the disease thereafter due to uncontrolled replication of the virus [20,21]. Live vaccines should be administered at least 4 weeks before starting immunosuppressive therapy.…”

Section: Two Main Types Of Vaccinesmentioning

confidence: 99%

Vaccination strategies for Korean patients with inflammatory bowel disease

Lee

Kim

2022

Korean J Intern Med

View full text Add to dashboard Cite

Patients with inflammatory bowel disease (IBD) are vulnerable to vaccine-preventable infectious diseases. Immunosuppressive drugs, which are often used to manage IBD, may increase this vulnerability and attenuate vaccine efficacy. Thus, healthcare providers should understand infectious diseases and schedule vaccinations for them to reduce the infection-related burden of patients with IBD. All patients with IBD should be assessed in terms of immunity to vaccine-preventable diseases at the time of IBD diagnosis, and be vaccinated appropriately. Vaccination is becoming more important because of the unprecedented coronavirus disease 2019 (COVID-19) global health crisis. This review focuses on recent updates to vaccination strategies for Korean patients with IBD.

show abstract

“…(Table 5) Hepatitis B titers should be assessed, as well, due to risk of reactivation in the setting of chronic inactive disease [26]. Patients with IBD should be vaccinated if not immune to these infectious agents but also receive hepatitis A&B, annual influenza, pneumonia (vaccines PCV-13 and PPSV23), inactivated Herpes zoster vaccine (if over 18 years of age or to initiate tofacitinib therapy), tetanus, diphtheria and pertussis (Tdap/Td), human papilloma virus (HPV) in those 11-26 and Neisseria meningitidis (if considered high risk per the CDC recommendations) [64,67]. (Table 5) Prior to initiating treatment with the immunomodulators azathioprine and 6-MP, measurement of thiopurine methyltransferase (TPMT) enzyme activity or genetic testing is advised [68].…”

Section: Preparation For Initiating Therapy For Ibdmentioning

confidence: 99%

Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate)

Sattler

Hanauer

Malter

2021

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Purpose of the ReviewAs treatment options for Inflammatory Bowel Disease (IBD) expand each class of medication will have specific safety concerns and side-effect profiles that need to be considered for optimal treatment of patients. We will review the most recent safety data for the newly approved immunomodulator therapies for the treatment of IBD. Recent Findings There are a growing number of publications outlining safety concerns for medications used to treat IBD. We reviewed safety profile of anti-tumor necrosis factor antibodies (TNF) with specific attention to combination therapy (anti-TNF plus immunomodulator). Recent publications have demonstrated increased risk of serious infection and malignancy (lymphoma and overall cancer rates) in patients receiving anti-TNF combination therapy when compared with patients receiving anti-TNF monotherapy or immunomodulator monotherapy. Recent publications on Janus Kinase Inhibitors indicate an increased risk of infection, specifically Herpes Zoster, and increased risk of major cardiovascular events and venous thromboembolic events resulting in a black box warning for the medication. In contrast, anti-interleukin 12/23 agents and gut selective anti-integrin antibody agents have demonstrated a favorable side-effect profile with low rates of infection and malignancy. The latest class of medications to be approved, sphingosine 1-phosphate (S1P) receptor modulators, have cardiac and infectious precautions. Summary The field of IBD treatment is rapidly evolving with several mechanistic classes of medications now available. While corticosteroids continue to be associated with the greatest, overall, safety risks, each of the newer mechanistic classes have unique safety concerns. In the future, as we gain more experience with these agents, we will need to continue to evaluate the safety profile of our therapies used alone or in combination to make informed treatment decisions with our patients.

show abstract

Updates on vaccinating the inflammatory bowel disease patient

Cited by 18 publications

References 89 publications

Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases

Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases

Vaccination strategies for Korean patients with inflammatory bowel disease

Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate)

Contact Info

Product

Resources

About